CLEVELAND, March 14, 2016 /PRNewswire/ -- ViewRay, Inc. (OTCQB: VRAY) announced today that the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, a national leader in cancer care, will be the first in the world to conduct studies with the innovative linear accelerator-based radiotherapy technology from ViewRay. This technology was recently announced at a healthcare investor conference; a copy of the presentation video can be found here. At this time, the MRIdian linac is available for non-clinical research use only.
Nearly two-thirds of all treated cancer patients in the United States will receive some form of radiation therapy during the course of their illness, according to estimates by the American Society for Radiation Oncology. Precision delivery of radiation therapy is a challenge because tumors and internal organs continually move during treatment. MRI-guidance improves the ability to aim radiation therapy directly at tumors, while avoiding surrounding tissues.
ViewRay has patented innovative solutions that enable the integration of MRI-guidance with a compact linac for radiation delivery. This breakthrough technology is being developed to be an upgrade to the current MRIdian system, the world's first and only MRI-guided radiation therapy system.
ViewRay worked with Washington University researchers to develop the original MRIdian system, and Siteman Cancer Center was the first center to treat patients on the MRIdian. The company again is working with Washington University to develop the capabilities of its next-generation linac-based technology.
"We look forward to evaluating the potential of this new linac-based technology to further advance cancer care," said Jeff Michalski, M.D., the Carlos Perez Distinguished Professor of Radiation Oncology and a member of Siteman Cancer Center.
"Researchers at Washington University are renowned for groundbreaking research that ultimately provides significant patient benefits," said Chris Raanes, president and CEO of ViewRay. "They played a leading role in the development, testing and clinical implementation of the MRIdian system, and we are delighted to have them as a research partner for our new linac technology."
ViewRay®, Inc. (OTCQB:VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation treatment. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the testing of ViewRay's MRIdian® linac technology, the number of cancer patients in the United States receiving radiation therapy and the benefits of MRIdian linac technology. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the MRIdian linac, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
SOURCE ViewRay, Inc.